Literature DB >> 10467390

Biological markers in body fluids for activity and progression in multiple sclerosis.

P S Sørensen1.   

Abstract

Reliable biological markers in body fluids for disease activity and progression are important for our understanding of the pathophysiology and therapeutic decisions in various subtypes of multiple sclerosis. Sampling from body fluids such as cerebrospinal fluid, blood, and urine constitutes the problem that the local immuno-inflammatory process takes place in the central nervous system whereas the disease activity is only to some extent reflected in the systemic immune compartment. Promising results have been obtained in studies of adhesion molecules, pro-inflammatory cytokines, co-stimulatory molecules and neopterin as markers of disease activity in relapsing-remitting multiple sclerosis. However, these results apply to groups of patients but not necessarily to individual patients. Currently no single body fluid marker is sufficiently correlated to disease activity to be used in the individual patient in monitoring disease activity, progression, or therapeutic effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10467390     DOI: 10.1177/135245859900500416

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  6 in total

1.  Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis.

Authors:  Makoto Matsui; Shin-ichi Araya; Hui-Yun Wang; Kouji Matsushima; Takahiko Saida
Journal:  J Neurol       Date:  2005-03-21       Impact factor: 4.849

Review 2.  Differentiation of multiple sclerosis subtypes: implications for treatment.

Authors:  Andreas Bitsch; Wolfgang Brück
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Cerebrospinal fluid in multiple sclerosis.

Authors:  Kottil W Rammohan
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

4.  Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients.

Authors:  Valentina Durastanti; Alessandra Lugaresi; Placido Bramanti; Mariapia Amato; Paolo Bellantonio; Giovanna De Luca; Orietta Picconi; Roberta Fantozzi; Laura Locatelli; Annalisa Solda'; Edoardo Sessa; Rocco Totaro; Silvia Marino; Valentina Zipoli; Marino Zorzon; Enrico Millefiorini
Journal:  J Transl Med       Date:  2011-04-18       Impact factor: 5.531

5.  Analogues of ERβ ligand chloroindazole exert immunomodulatory and remyelinating effects in a mouse model of multiple sclerosis.

Authors:  Hawra Karim; Sung Hoon Kim; Kelli Lauderdale; Andrew S Lapato; Kelley Atkinson; Norio Yasui; Hana Yamate-Morgan; Maria Sekyi; John A Katzenellenbogen; Seema K Tiwari-Woodruff
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

6.  Cerebrospinal Fluid Pterins, Pterin-Dependent Neurotransmitters, and Mortality in Pediatric Cerebral Malaria.

Authors:  Matthew P Rubach; Jackson P Mukemba; Salvatore M Florence; Bert K Lopansri; Keith Hyland; Ryan A Simmons; Charles Langelier; Sara Nakielny; Joseph L DeRisi; Tsin W Yeo; Nicholas M Anstey; J Brice Weinberg; Esther D Mwaikambo; Donald L Granger
Journal:  J Infect Dis       Date:  2021-10-28       Impact factor: 5.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.